Description
The MIH43 monoclonal antibody specifically binds to human B7-H4 (B7 family member, H4) that is encoded by the VTCN1 (V-set domain containing T cell activation inhibitor 1) gene. B7-H4 is a type I membrane glycoprotein with a calculated molecular weight of 30.89 kDa. It is also known as VCTN1, B7h.5, B7S1 (B7 superfamily member 1) or B7X. B7-H4 is a newly discovered member of the B7 family of costimulatory proteins. B7-H4 is not constitutively expressed on peripheral tissues. Its expression can be induced on macrophages, dendritic cells, B cells and T cells. By binding to its putative receptor, the function of B7-H4 was initially reported to be a negative regulator of T cell activation, proliferation and differentiation related to cytokine production and cytotoxic effector cell functions. B7-H4 is reportedly overexpressed in a variety tumors. B7-H4 expression by tumor macrophages appears to play a role in suppression antigen-specific T cell mediated immunity. Recent studies indicate that B7-H4 can also be a positive regulator of T cell responses. B7-H4 can be involved innate immunity as well, eg, by inhibiting neutrophil expansion.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Researchers should determine the optimal concentration of this reagent for their individual applications.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. CF™ is a trademark of Biotium, Inc.
7. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
